Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression

Next Previous
Trial Profile

An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Atazanavir; Darunavir; Fosamprenavir; Lopinavir; Ritonavir; Saquinavir
  • Indications HIV-1 infections
  • Focus Biomarker; Therapeutic Use
  • Acronyms NEAT022 Study

Most Recent Events

  • 12 Apr 2022 Results of a sub-study (n=86) assessed whether switching from a ritonavir-boosted PI-based regimen to a dolutegravir-based regimen improved the atherogenic properties of LDL particles in patients with HIV published in the Journal of Antimicrobial Chemotherapy
  • 13 Jun 2021 Results of sub-study assessing 48 weeks changes in biomarkers published in the Journal of Antimicrobial Chemotherapy
  • 31 Jul 2020 Results (n=156) assessing switching of boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk in sub-clinical CVD protocol, published in the Journal of Antimicrobial Chemotherapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top